Newsletter | January 30, 2025

01.30.25 -- End-To-End Solutions For Clinical Trials

What Does 2025 Hold For Pharma?

Look at what’s in store for pharma and life science in 2025. While we see many recurring themes, 2025 promises to be filled with unexpected — and possibly unprecedented — developments.

 

What's The Current & Future Impact Of AI On Pharmaceutical R&D?

Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing both the benefits and challenges of this innovative technology. With that in mind, Norstella, Citeline’s parent company, surveyed 125 senior decision-makers in the life sciences industry on their perceptions and expectations of AI to understand current AI adoption trends in addition to the future impact of AI on pharmaceutical R&D.

 

SOLUTIONS

How Can You Empower Sites To Recruit Patients With Precision?

Empower investigators to consider potential participants who precisely fit the protocol for your trial by alerting your site staff or CRO when these patients present at their site.

• Request Information

 

 

 

How Can You Simplify Disclosure Compliance For Global Clinical Trials?

Harness the power of TrialScope Disclose to manage the complexity of clinical trial disclosure and the risk of noncompliance. Track compliance across your entire trial portfolio, simplify and centralize disclosure processes, and work more efficiently to reduce data entry, review, and approval times by automating data requirements and reporting for clinical studies, protocol and results to global registries.

• Request Information

 

 

UPCOMING EVENT

 

See The Future Of Clinical Insight, At SCOPE

Don’t miss our exciting presentations, where our experts will share top tips on tackling diversity in clinical trials, harnessing the potential of AI, and boosting patient recruitment. See how Citeline’s actionable insights can help guide your next move, at Booth #608. Find out more and add the sessions to your calendar: SCOPE Summit 2025 | Citeline